These genetic interactions could suggest that the modeled SHRF amino acid substitution (Rrp4 G226D) has distinct in vivo consequences compared to the modeled multiple myeloma-associated substitution Rrp4 M68T. The gene discussed is EXOSC2; the disease is plasma cell myeloma.